$GLUE News

Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35

JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $31

Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Reports Q1 2026 Results as Clinical Progress Drives Focus on Upcoming Catalysts

Monte Rosa Therapeutics Q1 EPS $(0.45) Misses $(0.37) Estimate, Sales $4.210M Miss $10.883M Estimate

Monte Rosa Therapeutics, Inc. (GLUE) Presents at AACR Annual Meeting 2026 - Slideshow

Monte Rosa To Present Preclinical Data Highlighting Potential Of CCNE1-Directed MGD, MRT-55811, To Treat CCNE1-Amplified Solid Tumors At AACR Annual Meeting 2026

Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $30

Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $29

Monte Rosa Therapeutics Q4 EPS $(0.55) Misses $(0.33) Estimate, Sales $2.781M Miss $15.506M Estimate

Monte Rosa Highlights Updated Phase 1/2 Data Showing 67% Overall RECIST Disease Control And Tumor Reductions In Heavily Pretreated mCRPC

Monte Rosa Therapeutics Files Prospectus For Offering Mixed Shelf; Terms Not Disclosed

Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Raises Price Target to $37

Reported Earlier, Monte Rosa Therapeutics Prices $300M Underwritten Public Offering Of 11.125M Shares At $24.00 And 1.375M Pre-Funded Warrants

Reported Earlier, Monte Rosa Therapeutics Prices $300M Underwritten Public Offering Of 11.125M Shares At $24.00 And 1.375M Pre-Funded Warrants

Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $30

Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $34

Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation

Monte Rosa Therapeutics Terminates ATM Prospectus After Selling 2.96M Shares For $24.2M In Net Proceeds

Monte Rosa Therapeutics Commences Offering Of $200M Common Stock, Pre-Funded Warrants

Monte Rosa Therapeutics shares are trading higher after the company announced interim data from an ongoing Phase 1 clinical study evaluating MRT-8102.